TW201609814A - 新穎之抗ａｄａｍ１７抗體及其用於癌症治療的用途 - Google Patents

新穎之抗ａｄａｍ１７抗體及其用於癌症治療的用途 Download PDF

Info

Publication number
TW201609814A
TW201609814A TW103144955A TW103144955A TW201609814A TW 201609814 A TW201609814 A TW 201609814A TW 103144955 A TW103144955 A TW 103144955A TW 103144955 A TW103144955 A TW 103144955A TW 201609814 A TW201609814 A TW 201609814A
Authority
TW
Taiwan
Prior art keywords
antibody
adam17
sequence
amino acid
cdr
Prior art date
Application number
TW103144955A
Other languages
English (en)
Chinese (zh)
Inventor
彼得 羅威
Original Assignee
皮爾法伯製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 皮爾法伯製藥公司 filed Critical 皮爾法伯製藥公司
Publication of TW201609814A publication Critical patent/TW201609814A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW103144955A 2013-12-24 2014-12-23 新穎之抗ａｄａｍ１７抗體及其用於癌症治療的用途 TW201609814A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13306860 2013-12-24

Publications (1)

Publication Number Publication Date
TW201609814A true TW201609814A (zh) 2016-03-16

Family

ID=49920097

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103144955A TW201609814A (zh) 2013-12-24 2014-12-23 新穎之抗ａｄａｍ１７抗體及其用於癌症治療的用途

Country Status (13)

Country Link
US (1) US20160326257A1 (fr)
EP (1) EP3086808B1 (fr)
JP (1) JP2017501723A (fr)
KR (1) KR20160093723A (fr)
CN (1) CN106029094A (fr)
AR (1) AR098953A1 (fr)
AU (1) AU2014372539A1 (fr)
BR (1) BR112016014882A2 (fr)
CA (1) CA2935003A1 (fr)
MX (1) MX2016008478A (fr)
RU (1) RU2016129198A (fr)
TW (1) TW201609814A (fr)
WO (1) WO2015097287A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10858441B2 (en) * 2017-07-12 2020-12-08 University Of Macau Method of treatment for pancreatic cancer by administering a human-mouse cross-reactive ADAM 17 antibody
CN111040032B (zh) * 2018-10-11 2022-11-25 中国科学院上海营养与健康研究所 双向调节素在制备细胞衰老及肿瘤的诊断或调控制剂中的应用
WO2020185635A1 (fr) * 2019-03-08 2020-09-17 Memorial Sloan Kettering Cancer Center Molécules de liaison d'adam17 et leurs utilisations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005316217A1 (en) * 2004-12-17 2006-06-22 Memorial Sloan Kettering Cancer Center Regulation of metalloprotease cleavage of cell surface proteins
US9150659B2 (en) * 2011-02-01 2015-10-06 Gillian Murphy Anti-tace antibody molecules and their uses

Also Published As

Publication number Publication date
CA2935003A1 (fr) 2015-07-02
MX2016008478A (es) 2017-01-11
WO2015097287A1 (fr) 2015-07-02
AU2014372539A1 (en) 2016-07-21
CN106029094A (zh) 2016-10-12
BR112016014882A2 (pt) 2017-09-19
KR20160093723A (ko) 2016-08-08
US20160326257A1 (en) 2016-11-10
EP3086808B1 (fr) 2018-09-19
EP3086808A1 (fr) 2016-11-02
JP2017501723A (ja) 2017-01-19
RU2016129198A (ru) 2018-01-30
RU2016129198A3 (fr) 2018-08-21
AR098953A1 (es) 2016-06-22

Similar Documents

Publication Publication Date Title
CN112601762B (zh) 抗cd47抗体及其应用
JP2022130393A (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
TWI758558B (zh) Cd96抗體、其抗原結合片段及醫藥用途
KR102086656B1 (ko) Lrig-1 단백질에 특이적인 결합 분자 및 이의 용도
US20210388105A1 (en) Novel anti-cd39 antibodies
JP2018502050A5 (fr)
KR20210093255A (ko) 항-cd73 항체, 이의 항원 결합 단편 및 이의 적용
CN113527489B (zh) 抗cd73的抗体及其用途
CN111542546A (zh) 抗lag-3 抗体及其用途
CN111454358A (zh) 一种嵌合抗原受体及其应用
CN110790839A (zh) 抗pd-1抗体、其抗原结合片段及医药用途
WO2022194201A1 (fr) Anticorps ou fragment de liaison à l'antigène de celui-ci ciblant cldn18.2 et utilisation associée
WO2020063660A1 (fr) Anticorps anti-ox40, fragment de liaison à l'antigène de celui-ci, et utilisation pharmaceutique
JP2022513008A (ja) 融合タンパク質およびその使用
TW202222840A (zh) Ｃｄ７３的抗原結合蛋白及其應用
JP2022512749A (ja) Ｌｒｉｇ－１タンパク質に特異的な結合分子及びその用途
TW201609814A (zh) 新穎之抗ａｄａｍ１７抗體及其用於癌症治療的用途
WO2023001155A1 (fr) Anticorps de glypicane-3 et son utilisation
WO2021104052A1 (fr) Composition pharmaceutique, son procédé de préparation et son utilisation
US20180057601A1 (en) Novel humanized adam17 antibody
CN114478768A (zh) 抗cd73的抗体及其用途
CN114685657A (zh) 一种功能增强型抗体阻断剂的开发及其应用
WO2023016450A1 (fr) Anticorps anti-tigit et son utilisation
KR20230117183A (ko) 새로운 종양 인게이저 치료 약물의 개발 및 이의 용도
JP2023535233A (ja) グリコシル化ｃｅａｃａｍ５に特異的に結合した抗体